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Abstract: 
Background: Omalizumab has been shown to be effective in treating chronic spontaneous 
urticaria (CSU). The reduction of FcεRI receptor density on the surface of basophils and 
mast cells is thought to play a major role in its effectiveness. We conducted a double-blind, 
randomized, placebo-controlled trial to investigate the mode of action of omalizumab in 
patients with antihistamine-resistant CSU.   
Methods: Thirty patients were randomized in a 2:1 ratio to receive either 300 mg 
omalizumab or placebo. Four monthly applications of omalizumab/placebo were followed up 
with a visit 2 months after the last injection. The primary endpoint was the FcεRI receptor 
density change on basophils. 
Results: Omalizumab led to a significant reduction of FcεRI receptor density on 
basophils as soon as 1 week after the first injection: baseline omalizumab vs. placebo group, 
80.31 ± 47.18x10³ vs. 78.29 ± 45.09x10³ receptors/basophil ± SD; 1 week, 72.89 ± 47.79x10³  
vs. 27.83 ± 20.87x10³, p=0.001. This effect continued during the treatment phase and 
persisted for 2 months after the last injection: 93.81 ± 56.50x10³  vs. 21.09 ± 15.23x10³, 
p=0.002. Values for basophil “releasability” and the basophil activation test (CU-BAT) of 
patient serum using donor basophils were unchanged despite treatment: CU-BAT, CD63 
10.75% (7.35) in the placebo group vs. 8.35% (15.20) in the omalizumab group, p=0.778. 
Conclusion: We demonstrated a rapid reduction of FcεRI receptor density on basophils 
following treatment with omalizumab. Because CU-BAT using well-characterized, 
omalizumab-naïve donor basophils did not change during the treatment phase, autoreactive 
serum factors seem to remain unaltered. This points towards a cellular effect of omalizumab 
on basophils. To predict the omalizumab response time and to monitor disease, FcεRI 
density and CU-BAT might be promising cellular-based assays. 
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Introduction 
Chronic spontaneous urticaria (CSU) is a common disease with a point prevalence of 1% of 
the general population [1]. Patients manifest with hives on most days for a period of at least 6 
weeks. The disease is often accompanied by angioedema and tends to be cyclical in nature, 
with spontaneous disappearances and frequent relapses [2]. In most cases, no underlying 
disease or allergy can be found [3].  
 
CSU treatment relies mainly on second-generation antihistamines and is purely symptomatic. 
While some patients respond to standard-dose second-generation antihistamines, in others 
off-label (for CSU) treatments with high-dose H1-antihistamines, leukotriene receptor 
blocking agents, cyclosporine A, or systemic corticosteroids are needed [4, 5]. 
 
Based on several randomized controlled trials [6 – 8], the monoclonal anti-IgE antibody 
omalizumab was recently licensed for the treatment of antihistamine-resistant CSU [9]. The 
mechanism of action of omalizumab in CSU is still not fully understood. Omalizumab binds 
selectively to free IgE in plasma, inhibits its binding to FcεRI receptors on the surface of mast 
cells and basophils, and reduces the number of FcεRI receptors on basophils in atopic 
patients [10, 11] and those with CSU [12, 13]. A significant reduction of FcεRI receptor 
density on the surface of circulating basophils has been found as early as 1 week after the 
administration of omalizumab [14]. In contrast, a decrease in FcεRI receptor density on mast 
cells may occur later [11]. The role of basophils in CSU is still debated [15], but basophils 
may be an accessible and relevant model to analyze the effect of omalizumab on FcεRI 
expression and on the level of basophil activation.  
 
About half of CSU patients have autoantibodies against FcεRI, few against IgE [16, 17]. 
Other autoimmune markers such as IgE and IgG antibodies against thyroid peroxidase are 
frequently found [18]. Sera of CSU patients can activate the resting basophils of normal 
donors to release histamine and upregulate the activation markers CD63 and CD203c [19, 
20]. The basophil activation test with donor basophils (CU-BAT)  involves measuring CD63 
upregulation as an activation marker and is already established as a specific, sensitive, and 
safe in vitro assay to detect functional autoantibodies [19 – 22]. In addition, the FcεRI 
receptor density itself might be another important parameter for the quantification of mast cell 
and basophil “releasability” and therefore a good in vitro surrogate marker for their reactivity. 
 
To gain insight into the pathophysiology of some forms of CSU and the mode of action of 
omalizumab, we evaluated the effect of omalizumab treatment in patients with CSU by 
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investigating three parameters: FcεRI receptor density on the surface of basophils, 
determined by flow cytometry; the functional consequences of a change in FcεRI receptor 
density, evaluated via the crosslinking of FcεRI / IgE receptor complexes induced by 
autoantibodies (basophil releasibility); and whether typical CSU serum factors responsible for 
basophil degranulation were altered during treatment. Based on the findings of Gericke et al. 
[23], a post hoc analysis was performed to identify differences between early and slow 
responses to omalizumab. 
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Methods 
 
Study design 
In a monocentric, double-blind, randomized, placebo-controlled trial we investigated the 
mechanism of action of omalizumab in antihistamine-resistant CSU over a period of 7 
months, between September 2012 and April 2014. Thirty patients diagnosed with CSU were 
recruited and randomly assigned to two groups in a 2:1 ratio to receive either omalizumab 
(n=20) or placebo (n=10). Omalizumab (Xolair®) was administered in four monthly 
treatments at a fixed subcutaneous dose of 300 mg as currently licensed [6, 24]. Before the 
first administration, disease activity was assessed and documented over a 4-week period 
with the urticaria activity score (UAS), followed by the 16-week treatment period with 4 
injections of omalizumab/placebo. Two months after the last injection, a final study visit to 
follow up treatment efficacy and study outcomes took place.  
 
The study was approved by the local ethics committee and by Swissmedic, the Swiss agency 
for therapeutic products. The trial was conducted in accordance with the Declaration of 
Helsinki, the International Conference on Harmonisation (ICH)/WHO Good Clinical 
Practice, and all national, state, and local laws.  
 
This investigator-initiated study was funded by Novartis Pharmaceuticals (Basel, 
Switzerland). Their representatives were not involved in the design of the study or any data 
collection, analysis, or interpretation.  
 
Study population 
Patients between the ages of 18 and 70 with CSU were included in the study if they met the 
following criteria: symptoms for at least 6 weeks, with hives present at least twice weekly, 
and symptoms refractory to standard doses of H1-antihistamines at the time of 
randomization. Patients signed informed consent forms documenting their understanding of 
the study procedures and the investigational nature of the study. Exclusion criteria were 
purely inducible urticaria, clearly defined allergic urticaria, treatment with omalizumab during 
the last year, known hypersensitivity to omalizumab or any of its components, history of 
cancer in the previous 5 years, parasitic infections, documented active tuberculosis or 
ongoing recent (in the preceding 4 weeks) antituberculous therapy, documented prior 
treatment with systemic immunosuppressive agents (short-term prednisolone for CSU 
exacerbations was allowed), current pregnancy or nursing, known intolerance to any protocol 
intervention, and lack of accountability. Any contraception had to be performed by a safe, 
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reliable, and accepted method such as oral or implanted contraceptives or tubal ligation. 
Patients were allowed to take their usual medications (H1-antihistamines up to a fourfold 
single dose, H2-antihistamines, montelukast, short-term prednisolone for CSU 
exacerbations) for the treatment of CSU, but systemic immunosuppressive agents other than 
prednisolone were not permitted, as they might influence basophil assays.  
 
Basophil assays 
Two assays evaluated basophil phenotype and function, while another measured the 
presence of serum factors inducing donor basophil degranulation/activation.  
 
a) The FcεRI density on basophils was measured at randomization and on the day of 
the first treatment, and thereafter at 1 week, 1 and 3 months, and 2 months after 
stopping treatment. The FcεRI receptor density was assessed by QIFIKIT (Dako-
Cytomation, Glostrup, Denmark) according to the instructions of the manufacturer 
[25]. For each quantification, 500-1000 basophils were acquired using CCR3 
basophil-specific staining. FcεRI receptor density was defined according to the 
standard curve using beads with ascending predefined receptor densities. 
b) Basophil releasability was measured with and without IL-3 coincubation at three 
timepoints (baseline, 1 week, and 3 months after the first injection) by assessing the 
activation marker CD63 [26] after stimulation with anti-IgE (not omalizumab, Beckman 
Coulter, Krefeld Deutschland) at the concentrations of 1000, 100, 10 and 1ng/ml. 
Cells were stained with monoclonal anti-CD63-FITC antibodies (BioLegend, San 
Diego, CA, USA) and fluorescence was measured by FACSCanto® (Becton 
Dickinson AG, Allschwil, Switzerland) 
c) The CU-BAT involved incubating the serum of study participants on well-
characterized basophils from 10 donors both at baseline and at the last injection to 
detect the presence of activating serum factors. CD63 served as an activation 
marker, with expression data presented as the percentage of activated basophils and 
the stimulation index (SI), expressed as the percentage of activated basophils after 
stimulation with patient serum divided by the percentage of activated basophils 
without stimulation (negative control)  [22]. The donors were previously screened for 
reactivity to negative and positive controls as well as for basophil activation with 
different IL-3 concentrations. All serum samples were immediately stored at -20°C in 
aliquots to avoid repetitive freeze-thaw cycles. 
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Patient assessments 
All participants were required to document their symptoms once daily for 1 month using the 
urticaria activity score [27]. Medications taken were documented on their study 
questionnaires. 
 
Study endpoints 
The primary endpoint of the study was the FcεRI receptor density change on basophils 
during the first 12 weeks of treatment with omalizumab and 2 months after treatment. 
 
Secondary endpoints included comparison of basophil releasibility with and without IL-3 
incubation at three timepoints (baseline, 1 week, and 3 months); comparison of CU-BAT at 
baseline and 3 months; and change in the weekly urticaria activity score (UAS7) at baseline, 
3 months and 5 months. We evaluated the proportion of patients with a UAS7 of ≤6, a UAS7 
of 0, and an itch severity score (ISS) of 0.   
 
We summarized the proportion of patients who used H1- and H2-antihistamines, montelukast 
and prednisolone, and coded adverse events using the medical dictionary for regulatory 
activities (MeDRA) and their corresponding preferred terms and assigned body systems. 
 
Post hoc analysis 
Recently, Gericke et al. observed that the presence of autoreactive serum components 
predicted the response time to omalizumab treatment [23]. We therefore performed a post 
hoc analysis to identify differences in FcεRI-receptor density, autoreactive serum 
components (measured by CU-BAT), and total IgE in omalizumab partial/non-responders, 
early responders, and slow responders. Based on a previous report [23] we divided all study 
patients into 4 groups: placebo; partial/non-responder, defined as a UAS7 >6 at 3 months or 
a reduction of UAS7 to ≤6 or less at 3 months compared to baseline; early responder, 
defined as a treatment response within 8 days, with the first day of response determined as 
the first day of UAS7 <6; and slow responder, defined as a treatment response after 8 days 
but UAS7 <6 at 3 months. For each of these groups, we compared FcεRI receptor density, 
CU-BAT results, and total IgE at baseline, and calculated whether there was a difference in 
FcεRI density and CU-BAT between baseline and 3 months. 
 
Sample size determination 
A biological effect for the primary outcome was determined to be a difference of FcεRI 
receptor density of 45,000 per basophil, assuming a standard deviation of 40,000 Fc-IgE per 
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basophil. A power of 80%, a two-sided p-value of 0.05, and 2:1 randomization resulted in an 
overall sample size of 30 patients, with 20 in the active group and 10 in the placebo group. 
 
Analysis of primary, secondary, and other efficacy endpoints 
The primary endpoint, FcεRI receptor density, was analyzed using generalized estimation 
equations (GEE) with a negative binomial distribution family, log link, and robust standard 
errors due to strong skewness and heteroscedasticity when using mixed effects linear 
models. Treatment group and baseline receptor density were included as fixed effects. The 
mean of the two pretreatment visits was taken as the baseline receptor density. We report 
the ratio between treatments, with a ratio <1 indicating a reduction in receptor density. We 
used the same methods to analyze FcεRI receptor density at each follow-up time. 
 
Analysis of the primary endpoint followed the intention-to-treat (ITT) principle. Missing 
primary endpoint values were imputed by multiple imputation techniques using sequential 
chained equations based on baseline characteristics. Altogether, 12 of 150 (8.0%) FcεRI 
receptor measurements were missing, the majority at the last visit. 
 
As a sensitivity analysis, we also performed the main analyses on the per-protocol 
population. Twenty-four patients who completed all treatments according to the protocol were 
included. 
 
Secondary endpoints are summarized using descriptive statistics. Odds ratios (OR) for the 
UAS7 and ISS were calculated using penalized logistic regression by Firth’s method [28]. 
 
Analysis was performed using Stata 13.1 and 14 [29]. For all analyses we report estimates 
and 95% confidence intervals (CI) when relevant. Descriptive statistics report mean and 
standard deviation (SD) for continuous and normally distributed data or median and 
interquartile range (IQR) for non-normally distributed or highly skewed data. Count and 
percentages are reported for binary data. 
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Results 
 
Study Patients 
A total of 77 patients were screened, 41 of whom were excluded, 32 for good disease control 
with antihistamines, 4 for use of immunosuppressive drugs, 4 for spontaneous remission, 
and 1 for use of omalizumab in the last 12 months. Six patients declined to participate. Two 
patients in the placebo group withdrew consent as a consequence of disease progression, 
and two in the omalizumab group were lost to follow-up (Figure 1). 
 
Most baseline characteristics (age, weight, BMI) did not differ between the placebo and 
omalizumab groups (Table 1). The proportion of women was 80% in the placebo group and 
only 40% in the omalizumab group, but probably because of the small sample size. The 
UAS7 at baseline was 18.5 (11.3, 23.5) in the placebo group and 11.0 (2.5, 21.5) among 
omalizumab patients, while the ISS at baseline was the same in the two groups. Angioedema 
occurred in 53% of patients (70% in the placebo group, 45% in the omalizumab group). 
Disease duration was 27.0 (19.8, 64.8) months in the placebo group and 19.5 (12.0 33.8) in 
the omalizumab group. 
There were eight partial/non-responders, seven early responders, and two slow responders 
in the omalizumab group; three patients who dropped out could not be classified. There were 
no partial responders.  
 
FcεRI receptor density 
At baseline, no significant differences in FcεRI receptor density were found between the two 
groups (Figure 2, Table 6). Compared to placebo, 300 mg of omalizumab led to a rapid and 
significant reduction of FcεRI receptor density as soon as 1 week after the first injection 
(72.89 ± 47.79x10³ vs. 27.83 ± 20.87x10³ receptors/basophil, respectively, p=0.001). Again 
compared to placebo, the receptor density in the omalizumab group remained low throughout 
the treatment period (values at 3 months: 95.88 ± 54.17x10³ vs. 17.47 ± 21.41x10³, 
respectively, p=<0.001), and was still low at 2 months after the last injection (93.81 ± 
56.50x10³ vs. 21.09 ± 15.23x10³, respectively, p=0.002). 
 
Basophil releasability 
Regarding basophil releasability, expressed as Log10 of the anti-IgE (not omalizumab) 
concentration resulting in half-maximal activation of basophils (LC50), no significant 
difference of the LC50 value could be found between the two groups at the start of treatment 
(with or wthout IL-3). Treatment did not result in a consistent change of releasibility (Table 
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2a). Interestingly, the basophil releasability measured with IL-3 coincubation decreased in 
the omalizumab group during the study (higher values indicate lower basophil releasability). 
However, due to the small sample size, statistical significance cannot be shown.  
 
 
Effect of omalizumab on serum factors 
Patient serum was incubated twice with third-party donor basophils (at baseline and at 3 
months). Compared to placebo, the percentage of activated donor basophils was slightly 
higher in the omalizumab group at baseline: the CD63 positivity was 12.05% (10.80) vs. 
18.35% (17.77), respectively, p=0.244; the SI values were similar, 4.20 (5.50) vs. 5.00 (7.20), 
respectively, p=0.535. There was no significant difference in either parameter between the 
placebo and omalizumab groups, both at baseline and the last injection: CD63 positivity, 
10.75% (7.35) vs. 8.35% (15.20), respectively, p=0.778; SI, 3.20 (2.45) vs. 2.75 (3.50), 
respectively, p=0.847. Treatment did not significantly affect the activity of these serum factors 
(Table 2b).  
 
CSU activity 
The UAS7 was summed for a week before each study visit, and the proportions of patients 
with mild (UAS7 of ≤6) or no symptoms (UAS7=0) were evaluated. The proportion of patients 
with no itching (ISS=0) in the week before the corresponding visit was also assessed (Table 
3).  
 
We observed no significant differences at baseline in UAS7≤6 (OR 1.47; 0.26, 8.43) or ISS=0 
(1.21; 0.15, 9.92) between the placebo and omalizumab groups. We observed a significant 
difference in the proportion of patients with mild symptoms (UAS7 <=6) at the time of the last 
injection (7.80; 1.28, 47.53); it was increased in the omalizumab group (76%) but remained 
unchanged in the placebo group (25%). The proportion of patients with ISS=0 showed no 
significant difference between the two groups; the odds of having a score of 0 were higher in 
the omalizumab group, though the difference was not statistically significant (both 15.21; 
0.76, 305.06). Two months after the last injection, the proportion of patients with UAS7≤6 
and ISS=0 showed no significant difference between the placebo and omalizumab groups. 
 
Post hoc analysis 
In a post hoc analysis we classified all study patients into 4 groups: placebo, partial/non-
responder, early responder, and slow responder (Table 4). At baseline, FcεRI density was 
equal among the placebo, slow responder, and early responder groups, but lower in the 
partial/non-responder group (p=0.094). Compared to placebo, there was a reduction of the 
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FcεRI density on basophils in all three treatment groups, although the partial/non-responder 
group demonstrated the least reduction: -45.3x10³ (-74.9;  0.3) receptors per basophil in the 
partial/non-responder group, -99.7x10³ (-138.9; -60.5) in the slow responder group, and -
91.7x10³ (-154.3; -63.7) in the early responder group). As a sign of autoreactive serum 
components at baseline, CU-BAT results in the omalizumab group were highest in the 
partial/non-responder group (CD63 positivity 26.3% (8.7; 44.6)) and lowest in the early 
responder group (CD63 positivity 17.1% (4.5;  24.8)), though these differences were not 
statistically significant. There was a slight but nonsignificant reduction of the CU-BAT in all 
three treatment groups. Two patients in the partial/non-responder group had an increase of 
CU-BAT under omalizumab treatment. The total IgE values at baseline were lowest in the 
partial/non-responder group. 
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Discussion 
We found that treatment with omalizumab resulted in a rapid and significant reduction of 
FcεRI density on basophils, which is consistent with previous studies [10, 11, 14] and 
confirms the results of Deza et al. [12] and Metz et al. [13]. This reduction was observed as 
soon as 1 week after the initiation of treatment and remained reduced for at least 2 months 
after the last omalizumab application (last study visit), although CSU often flares up by this 
later timepoint. The reduction of FcεRI density is thought to be one of the central 
mechanisms of omalizumab’s action in CSU [30]. In accordance with recent findings [12], 
FcεRI density at baseline was reduced in patients who did not respond to this therapy. The 
partial/non-responder group demonstrated the least reduction of the FcεRI density under 
omalizumab treatment. Correspondingly, post hoc analysis showed that total IgE values 
before treatment were lowest in partial/non-responders.  
 
We expected a reduction of basophil releasability, applying titrated concentrations of 
degranulating anti-IgE (not omalizumab) to patient basophils. However, this was not the 
case. Investigation of basophil releasability using a high-affinity degranulating anti-IgE 
antibody, even in titrated form, might produce a signal too intense to show subtle differences 
in basophil releasability. Basophil stimulation with an allergen (in sensitized individuals) might 
have led to different results. Unfortunately, the study included only nine pollen-sensitized 
patients, which was too few to confirm this hypothesis. Interestingly, treatment with 
omalizumab has been shown to lead to increased sensitivity of basophils using IgE-mediated 
stimuli [31], a phenomenon that is not fully understood. In addition, no alteration of mast cell 
or basophil histamine release was observed when cells were coincubated with omalizumab 
in vitro [32], but this might not reflect the in vivo activity of omalizumab. 
 
We investigated changes of autoreactive serum factors, which may occur in CSU patients, 
during omalizumab treatment. By coincubating well-characterized donor basophils with the 
serum of CSU patients (CU-BAT), the omalizumab-treated basophils of the patient are 
replaced by treatment-naïve donor basophils, which allows a focus on transferable serum 
factors alone. Again, no difference was found between the two study groups either at 
baseline or over time. This suggests that omalizumab does not interact with or alter 
autoreactive or other urticaria-promoting serum factors. However, CU-BAT results were very 
heterogeneous and the sample size was small, which hampered the statistical analysis. 
Interestingly, higher CU-BAT results at baseline were associated with slow or partial/non-
response to omalizumab, with partial/non-responders having the highest values, findings that 
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are consistent with those of Gericke et al. [23]. Two partial/non-responders even 
demonstrated an increase in CU-BAT under omalizumab treatment.  
 
While CSU is a mast cell-driven disease, our experimental approach relied on basophils due 
to their better accessibility and the assumptions that a) basophils play a relevant role in the 
pathogenesis of CSU [13, 20], and b) analysis of basophil activity is a relevant model for 
changes of omalizumab-induced mast cell activity. While omalizumab does not lead to a 
significant reduction of autoreactive serum components, its effect might rely on cellular 
changes. It is well known that circulating basophils are recruited into skin lesions in CSU [33 
- 35]. It is possible that omalizumab decreases the ability of basophils to migrate into the 
skin, for example by altering their chemokine receptor repertoire. Consistent with this 
hypothesis, Metz et al. showed a decrease in the number of FcεRI+ skin cells under 
omalizumab treatment [13] 
 
Our study population was heterogeneous: 6 of our 30 patients had a changing disease 
course with only mild symptoms at baseline compared to the time of study inclusion. This 
reflects the natural course of CSU, which is characterized by intermittent remissions, and 
might explain the nonsignificant differences in various endpoints. Furthermore, as we 
intended to study patients with severe forms of CSU, there were eight partial/non-
responders. This probably influenced the study outcomes, but gave us the opportunity to 
identify differences between slow, early, and partial/non-responders. 
 
CSU tends to remit spontaneously, and thus far no sustained disease-modifying effect of 
omalizumab has been documented after the medication is discontinued. Furthermore, the 
response time after initiating omalizumab treatment varies greatly. FcεRI density on 
basophils, CU-BAT, and total IgE might be appropriate parameters to predict response time 
and disease course under omalizumab. Assessing these factors before initiating treatment 
with omalizumab could help differentiate between early, slow, and partial/non-responders. In 
particular, low FcεRI density and/or high CU-BAT at baseline might predict whether a patient 
will be a partial/non-responder. Practically speaking, it would be even easier to determine the 
total IgE value at baseline, as it corresponds to FcεRI density, meaning that a low total IgE 
predicts a low FcεRI density.  
In patients who respond to omalizumab, treatment discontinuation is necessary to reveal the 
underlying disease status. As omalizumab did not lead to a reduction of CU-BAT, a 
disappearance of autoreactive serum components under omalizumab treatment might 
indicate remission of CSU. However, this assumption would only be valid in CU-BAT-positive 
CSU patients (approximately 30-40% of all CSU patients).  
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Conclusion 
This study contributes to understanding CSU pathogenesis and the mode of action of 
omalizumab. It substantiates the previous observation that the reduction of FcεRI density is 
rapid and sustained. The clinical efficacy of omalizumab did not correlate with serum 
changes (CU-BAT results remained stable throughout the study period). This points towards 
a primarily cellular effect of omalizumab on basophils. To predict the response time of 
omalizumab and for disease monitoring, FcεRI density and CU-BAT are promising cellular-
based tests if used before treatment initiation.  
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Figures and tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Enrollment and allocation 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=77 ) 
Randomized (n=30) 
Allocated to omalizumab (n=20) 
Received allocated intervention (n=20) 
Allocated to placebo (n=10) 
Received allocated intervention (n=10) 
Patients not finishing the study = 2 
Reasons: 
Withdrawal of consent: (n=2) 
Patients not finishing the study = 2 
Reasons: 
Lost to follow up: (n=2) 
Analyzed, intention to treat: 10 
Analyzed, per protocol: 7 
 
Missing measure v6 = 2 
Missing measure v7 = 2 
 
Analyzed, intention to treat: 20 
Analyzed, per protocol: 17 
 
Missing measure v6 = 2 
Missing measure v7 = 3 
Excluded (n=47 ) 
Not meeting inclusion criteria (n=41) 
Declined to participate (n=6) 
Other reasons (n=0) 
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Table 1 Baseline characteristics 
  Placebo Omalizumab p Value 
        
  N=10 N=20   
        
Demographics 
      
 Age (at inclusion)     42.4 ± 13.3       41.8 ± 15.2    0.915  
 Gender (female)       8 (80%)           8 (40%)      0.058  
 Weight (kg)     76.9 ± 16.9       83.6 ± 20.1    0.375  
 Height (cm)    164.7 ±  8.3      174.1 ±  8.1    0.006  
 Body mass index (kg/m2)     28.3 ±  6.0       27.5 ±  7.1    0.764  
Clinical 
      
 Duration of disease (months)  27.0 (19.8; 64.8)  19.5 (12.0; 33.8)  0.180  
 Angioedema (yes)       7 (70%)           9 (45%)      0.433  
Urticaria activity score for 1 
week (UAS7) at baseline 
 18.5 (11.3; 23.5)  11.0  (2.5; 21.5)  0.187  
 Itch severity score at baseline   8.0 (1.8; 12.0)   8.0 (1.8; 13.5)  1.000  
 Allergy to birch pollen (Yes)       2 (20%)           5 (25%)      1.000  
 Allergy to grass pollen (Yes)       4 (40%)           4 (20%)      0.384  
 Study complete (Yes)       8 (80%)          18 (90%)      0.584  
Values are mean ± standard deviation for continuous variables, or median and interquartile ranges (IQR) for non-
normally distributed or highly skewed variables. Categorical variables reported as n (%).  
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Figure 2 FcεRI receptor density (mean and 95% CI) at baseline, 1 week, 1 month, 3 months, and 5 
months (crude values) 
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Table 2a Basophil releasability after stimulation with anti-IgE (not omalizumab)   
Variable Visit no. Placebo (median 
[IQR]) 
Omalizumab (median 
[IQR]) 
p (unadj.) Ratio adjusted for 
baseline (95% CI) 
p 
(Ratio) 
       
Basophil releasability (LC50) without IL-3 Baseline 29.50 (69.61) 27.95 (57.80) 0.903 0.68 (0.25, 1.83)* 0.446* 
(ng/ml) 1 Week  39.95 (103.75)  57.20 (228.64)  0.77 (0.20, 3.00) 0.691 
 3 Months 93.60 (86.20) 23.30 (31.86)  0.33 (0.07, 1.52) 0.142 
 
Basophil releasability (LC50) with IL-3 Baseline 12.55 (19.27) 8.27 (12.85) 0.903 2.03 (0.85, 4.81)* 0.110* 
(ng/ml) 1 Week 12.23 (38.91) 32.00 (49.26)  1.24 (0.40, 3.86) 0.693 
  3 Months 20.70 (58.03) 30.65 (143.80)   2.81 (0.62, 12.71) 0.164 
Values are calculated as LC50 (Log10 of anti-IgE concentration in ng/ml resulting in half-maximal activation of basophils). Higher values indicate lower basophil releasability. 
Median and interquartile range (IQR) are each measured with two methods. P (unadj.) from Wilcoxon’s rank-sum test for baseline values. Ratios and p for ratios calculated from 
linear regression models on log-transformed data for specific times, or from a mixed-effects model including patient ID as a random effect for a repeated measures analysis (*). 
Table 2b Incubation of patient serum with donor basophils (CU-BAT). 
Variable Visit no. Placebo (median [IQR]) Omalizumab (median [IQR]) p (unadj.) Ratio adjusted for 
baseline (95% CI) 
p 
(Ratio) 
CU BAT: CD63 (%) Baseline 12.05 (10.80) 18.35 (17.77) 0.244   
 3 Months 10.75 (7.35) 8.35 (15.20)  0.90 (0.42, 1.92) 0.778 
 
CU BAT: CD63 (Stimulation index) Baseline 4.20 (5.50) 5.00 (7.20) 0.535   
 3 Months 3.20 (2.45) 2.75 (3.50)  0.93 (0.44, 1.99) 0.847 
 
       
CD63 served as an activation marker and is expressed as the percentage of activated basophils. The stimulation index is expressed as the percentage of activated basophils after 
stimulation with patient serum divided by the percentage of activated basophils without stimulation (negative control). Median and interquartile range (IQR) are each measured with 
two methods. P (unadj.) from Wilcoxon’s rank-sum test for baseline values. Ratios and p for ratios calculated from linear regression models on log-transformed data for specific 
times, or from a mixed-effects model including patient ID as a random effect for a repeated measures analysis (*).  
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Table 3 Urticaria activity score over 1 week (UAS7) and itch severity score (ISS) 
Measure Placebo (n=8) Omalizumab (n=17) OR (95% CI) 
Baseline    
   UAS7 ≤ 6 2 6* 1.47 (0.26, 8.43) 
   UAS7 = 0 0 3* 4.10 (0.19, 89.44) 
   ISS = 0 1 3* 1.21 (0.15, 9.92) 
3 Months    
   UAS7 ≤ 6 2 13 7.80 (1.28, 47.53) 
   UAS7 = 0 0 8 15.21 (0.76, 305.06) 
   ISS = 0 0 8 15.21 (0.76, 305.06) 
5 Months    
   UAS7 ≤ 6 2 9 2.91 (0.52, 16.35) 
   UAS7 = 0 1 4 1.67 (0.21, 12.97) 
   ISS = 0 1 4 1.67 (0.21, 12.97) 
Confidence intervals from penalized logistic regressions. 
Urticaria activity score (UAS7) was summed for a week before the above times and evaluated for the proportions of patients with mild (UAS7≤6) or no symptoms (UAS7=0). ISS 
was evaluated for the proportion of patients with no itching (ISS=0) in the week before the corresponding visit.  Odds ratios (OR) for the UAS7 and ISS were calculated. 
* At time of study inclusion, all patients had UAS7>6. 
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Table 4 
Comparison of FcεRI density (receptors per basophil), incubation of patient serum on donor basophils (CU-BAT: CD63 %), and total IgE (kU/L) in partial/non-
responders, slow responders, and early responders 
All Placebo 
Partial/Non-
responders Slow responders Early responders p Value 
n (%) or median (IQ-
range) 
n (%) or median (IQ-
range) 
n (%) or median 
(IQ-range) 
n (%) or median (IQ-
range) 
n (%) or median (IQ-
range) 
Total N N=25 N=8 N=8 N=2 N=7 
FceRI density at baseline 90.9 (55.9; 138.1) 97.6 (46.8; 133.9) 55.9 (28.6; 87.9) 113.7 (71.2; 156.2) 104.0 (81.0; 162.8) 0.094 
Difference of FcεRI density (Basline 
to 3 months) -48.0 (-89.1;  5.8)   7.8 (-15.0; 16.9) -45.3 (-74.9; 0.3) -99.7 (-138.9; -60.5) -91.7 (-154.3; -63.7) 0.002  
CU-BAT at baseline (%) (BL)   13.8 (7.8; 27.8) 11.6 (7.2; 17.9)   26.3 (8.7; 44.6)   20.3 (13.7;  26.9)   17.1 (4.5;  24.8) 0.438  
Difference of CU-BAT (Baseline to 3 
months)   -3.2 (-14.5;  0.4)   0.2  (-9.7;  2.1)   -4.6 (-25.9;  2.2) -17.0  (-24.1;  -9.8)   -4.9  (-13.1;   0.1) 0.408  
Total IgE at baseline (kU/L) 137.0 (37.8; 311.0) 
 
   
222.0 (55.8; 1377.8) 
 
   
  25.0 (10.8; 226.5) 
 
296.0 (273.0; 319.0) 
 
113.5 (59.5; 368.5) 
 
0.182  
 
We compared different biological effects among the patients classified into 4 groups (placebo, partial/non-responder, slow responder, and early responder) using 
the chi-squared test and the non-parametric Kruskal-Wallis rank test as appropriate. We compared the FcεRI receptor density, CU-BAT results (i.e., CD63 
change), and total IgE values at baseline, and calculated whether there was a difference of FcεRI receptor density and CU-BAT between baseline and 3 months.
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Table 5 Summary of adverse events by body system (count per group) 
  Intervention     
Body system Placebo Omalizumab Total 
 No. No. No. 
Cardiovascular disorder 2 1 3 
General disorder 6 6 12 
Infections 3 3 6 
Musculoskeletal and connective tissue disorder 0 1 1 
Nervous system disorder 1 1 2 
Skin tissue disorder 0 1 1 
Total 12 13 25 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
 
Table 6 FcεRI receptors per basophil: estimates and summaries  
          Ratio adjusted for 
baseline (95% CI) 
      
Analysis Placebo group N Omalizumab group   N ITT p PP p 
Overall FcεRI density  10  20 0.32 (0.23 ,0.44) <0.001 0.22 (0.14, 0.33) <0.001 
         
FcεRI density at each 
visit 
        
Baseline 80.31 ± 47.18x10³ 10 78.29 ± 45.09x10³ 20 0.97 (0.63, 1.50) 0.908 0.82 (0.56, 1.19) 0.288 
1 Week 72.89 ± 47.79x10³ 10 27.83 ± 20.87x10³ 18 0.48 (0.31, 0.73) 0.001 0.37 (0.25, 0.54) <0.001 
1 Month 86.09 ± 43.60x10³ 9 15.46 ± 8.41x10³ 20 0.23 (0.15, 0.34) <0.001 0.16 (0.11, 0.24) <0.001 
3 Months 95.88 ± 54.17x10³ 8 17.47 ± 21.41x10³ 18 0.20 (0.12, 0.35) <0.001 0.13 (0.09, 0.17) <0.001 
5 Months 93.81 ± 56.50x10³ 8 21.09 ± 15.23x10³ 17 0.36 (0.19, 0.68) 0.002 0.23 (0.15, 0.35) <0.001 
Ratios of omalizumab over placebo taken from the generalized estimation equations (GEE) model with log link and negative-binomial distribution due to highly skewed distributions 
and heteroscedasticity. For intention-to-treat (ITT) analysis, all patients were included in the groups they were randomized to; missing values were imputed using multiple 
imputations. Summary statistics (mean ± SD) are given for times at and after the first application of omalizumab; GEE ratios are adjusted for baseline values. PP = Per protocol. 
 
Table 7 – Summary of rescue medication usage during the whole trial period 
Medication Cumulative frequency (95% CI) Percentage of patients taking 
rescue medication 
Cumulative frequency. per 
day (95% CI) 
  Placebo Omalizumab Placebo Omalizumab Placebo Omalizumab 
H1 Anti-
histamines 
382.0 (255.1, 
508.9) 
347.0 (239.7, 
454.3) 
100.0 (69.2, 
100.0) 
100.0 (83.2, 
100.0) 
2.8 (2.1, 
3.5) 
2.5 (1.8, 3.3) 
H2 Anti-
histamines 
  40.0 (12.2, 73.8) 30.0 (11.9, 54.3)   
Prednisone   0.0 (0.0, 30.8) 10.0 (1.2, 31.7)   
Montelukast 77.8 (20.5, 
135.1) 
54.9 (26.5, 83.2) 60.0 (26.2, 87.8) 65.0 (40.8, 84.6) 1.0 (1.0, 
1.0) 
1.0 (0.9, 1.0) 
The percentages of patients who used rescue medications and the frequency of use of the rescue medications are summarized by means of descriptive statistical techniques (per 
group). 
